Cargando…

Hypersensitivity Reactions to Native E. coli L-asparaginase in Children With Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction

Detalles Bibliográficos
Autores principales:	Möricke, Anja, Rizzari, Carmelo, Alten, Julia, Attarbaschi, Andishe, Beier, Rita, Biondi, Andrea, Burkhardt, Birgit, Bodmer, Nicole, Boos, Joachim, Cario, Gunnar, Conter, Valentino, Flotho, Christian, Kulozik, Andreas, Lanvers-Kaminsky, Claudia, Mann, Georg, Niggli, Felix, Silvestri, Daniela, von Stackelberg, Arend, Stanulla, Martin, Valsecchi, Maria-Grazia, Schrappe, Martin, Zimmermann, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238044/ https://www.ncbi.nlm.nih.gov/pubmed/37275738 http://dx.doi.org/10.1097/HS9.0000000000000888

Ejemplares similares

Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol
por: Rizzari, Carmelo, et al.
Publicado: (2023)

Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia
por: Khalil, Alaeddin, et al.
Publicado: (2020)

Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study
por: Rizzari, Carmelo, et al.
Publicado: (2019)

Invasive fungal diseases impact on outcome of childhood ALL – an analysis of the international trial AIEOP-BFM ALL 2009
por: Lehrnbecher, Thomas, et al.
Publicado: (2022)

Effect of two additional doses of intrathecal methotrexate during induction therapy on serious infectious toxicity in pediatric patients with acute lymphoblastic leukemia
por: Heilmann, Janina, et al.
Publicado: (2023)

Frequency and prognostic impact of PAX5 p.P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP‐BFM acute lymphoblastic leukemia protocol
por: Jung, Mareike, et al.
Publicado: (2020)

Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data
por: Würthwein, Gudrun, et al.
Publicado: (2021)

Chemotherapy-related hyperbilirubinemia in pediatric acute lymphoblastic leukemia: a genome-wide association study from the AIEOP-BFM ALL study group
por: Junk, Stefanie V., et al.
Publicado: (2023)

Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemia
por: Schieck, Maximilian, et al.
Publicado: (2020)

Impact of Antibodies Against Polyethylene Glycol on the Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukaemia: A Population Pharmacokinetic Approach
por: Siebel, Christian, et al.
Publicado: (2021)

Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols
por: Cario, Gunnar, et al.
Publicado: (2020)

Tumor necrosis factor and lymphotoxin-alpha genetic polymorphisms and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study of patients treated with BFM therapy
por: Stanulla, Martin, et al.
Publicado: (2001)

Genetic polymorphisms of the lymphotoxin alpha gene are associated with increased risk for lethal infections during induction therapy for childhood acute leukemia: a case-control study
por: Kidas, Ekaterini, et al.
Publicado: (2009)

Dose-adjusted EPOCH-rituximab or intensified B-non-Hodgkin lymphoma therapy for pediatric primary mediastinal large B-cell lymphoma. Results from the study B-NHL-BFM-04 and the NHL-BFM registry 2012
por: Knörr, Fabian, et al.
Publicado: (2021)

P322: DECIPHERING THE UNDERLYING MOLECULAR COMPLEXITY OF THE IKZF1PLUS SIGNATURE
por: Lühmann, Jonathan, et al.
Publicado: (2023)

Methotrexate-associated toxicity in children with Down syndrome and acute lymphoblastic leukemia during consolidation therapy with high dose methotrexate according to ALL-BFM treatment regimen
por: Kroll, Mirko, et al.
Publicado: (2020)

Can Machine Learning Models Predict Asparaginase-associated Pancreatitis in Childhood Acute Lymphoblastic Leukemia
por: Nielsen, Rikke L., et al.
Publicado: (2022)

The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL–BFM 2000 protocol can be separated from FBXW7 loss of function
por: Kox, C, et al.
Publicado: (2010)

PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma
por: Zheng, Wen, et al.
Publicado: (2017)

BCR-ABL1-like acute lymphoblastic leukemia in childhood and targeted therapy
por: Cario, Gunnar, et al.
Publicado: (2020)

Asparaginase pharmacokinetics and implications of therapeutic drug monitoring
por: Asselin, Barbara, et al.
Publicado: (2015)

Trypsin-encoding PRSS1-PRSS2 variations influence the risk of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a Ponte di Legno toxicity working group report
por: Wolthers, Benjamin O., et al.
Publicado: (2019)

Second malignancies after treatment of childhood non-Hodgkin lymphoma – a report of the Berlin-Frankfurt-Muenster study group
por: Moser, Olga, et al.
Publicado: (2020)

PAX5-AUTS2: A recurrent fusion gene in childhood B-cell precursor acute lymphoblastic leukemia
por: Denk, Dagmar, et al.
Publicado: (2012)

Implementation of the asparaginase activity assessment technique for clinical use: experience of a Brazilian Center
por: Cecconello, Daiane Keller, et al.
Publicado: (2020)

Second malignant neoplasms after treatment of 1487 children and adolescents with acute lymphoblastic leukemia—A population‐based analysis of the Austrian ALL‐BFM Study Group
por: Poyer, Fiona, et al.
Publicado: (2022)

The Clinical Utility of Optical Genome Mapping for the Assessment of Genomic Aberrations in Acute Lymphoblastic Leukemia
por: Lühmann, Jonathan Lukas, et al.
Publicado: (2021)

Repurposing anthelmintic agents to eradicate resistant leukemia
por: Mezzatesta, Caterina, et al.
Publicado: (2020)

P333: SUBCLONAL AND CLONAL VARIANTS IN TP53 AND KRAS COMBINED WITH POOR TREATMENT RESPONSE IDENTIFY A SUBGROUP OF ULTRA-HIGH-RISK PATIENTS OF PEDIATRIC T-LYMPHOBLASTIC LEUKEMIA (T-ALL)
por: Kempter, Tamara, et al.
Publicado: (2023)

Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia
por: Palmi, Chiara, et al.
Publicado: (2023)

Back to the future: the amazing journey of the therapeutic anti-leukemia enzyme asparaginase Erwinia chrysanthemi
por: Tong, Wing H., et al.
Publicado: (2023)

Hepatic sinusoidal obstruction syndrome and short-term application of 6-thioguanine in pediatric acute lymphoblastic leukemia
por: Stanulla, Martin, et al.
Publicado: (2021)

Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and susceptibility to pediatric acute lymphoblastic leukemia in a German study population
por: Schnakenberg, Eckart, et al.
Publicado: (2005)

Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias
por: Shochat, Chen, et al.
Publicado: (2011)

Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias
por: Shochat, Chen, et al.
Publicado: (2011)

S111: TREATMENT OF POST-TRANSPLANT RELAPSE IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH BCP ALL USING CD19-CAR-T: A EUROPEAN RETROSPECTIVE ANALYSIS OF REAL-WORLD DATA
por: Bader, Peter, et al.
Publicado: (2023)

Genetic Variation in ABCC4 and CFTR and Acute Pancreatitis during Treatment of Pediatric Acute Lymphoblastic Leukemia
por: Bartram, Thies, et al.
Publicado: (2021)

Transcriptional and Mutational Profiling of B-Other Acute Lymphoblastic Leukemia for Improved Diagnostics
por: Chouvarine, Philippe, et al.
Publicado: (2021)

Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL
por: Locatelli, Franco, et al.
Publicado: (2022)

Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004
por: Rasche, M, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8d9ugcrk6kf1379nit72ge70gb